Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Alamar Biosciences, Inc. (ALMR)

Alamar Biosciences Q2 revenue up 82% to $29.4 million; sets 2026 revenue guidance

Mixed Impact 3 of 5 earnings Written later

Alamar Biosciences reported second-quarter 2026 revenue of $29.4 million, up 82% from a year earlier, and gave full-year 2026 revenue guidance of $116 million to $120 million. The net loss widened to $13.2 million from $7.0 million as operating expenses rose 89%, so shareholders face strong sales growth alongside a larger loss.

Key points

  • Q2 2026 total revenue was $29.4 million, up from $16.2 million in Q2 2025; consumable revenue rose 147% to $15.5 million
  • Q2 2026 net loss was $13.2 million versus $7.0 million a year earlier; operating expenses rose to $31.2 million from $16.5 million
  • Full-year 2026 revenue guidance is $116 million to $120 million, growth of 59% at the midpoint versus 2025
  • Cash, cash equivalents, short-term investments and restricted cash totaled $256.3 million as of June 30, 2026

The filing

CompanyAlamar Biosciences, Inc. (ALMR)
Form8-K, current report
Filed with the SECAug 10, 2026, 4:10 PM ET
Accession number0001193125-26-342378

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:48 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.